Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 5, 2003, Pages 1681-1688

  Karlowsky, James A ^a   Draghi, Deborah C ^a   Jones, Mark E ^b   Thornsberry, Clyde ^c   Friedland, Ian R ^d   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (Netherlands)

^c Focus Technologies   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TIMENTIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; HOSPITAL LABORATORY; HOSPITALIZATION; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; UNITED STATES;

EID: 0038673434     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.5.1681-1688.2003     Document Type: Article

References (32)

1. Bert, F., E. Maubec, B. Bruneau, P. Berry, and N. Lambert-Zechovsky. 1998. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tapwater in a neurosurgery intensive care unit. J. Hosp. Infect. 39:53-62.
2. Bou, G., G. Cerveró, M. A. Domínguez, C. Quereda, and J. Martínez-Beltrán. 2000. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of 32 β-lactamases. J. Clin. Microbiol. 38:3299-3305.
3. Bou, G., A. Oliver, and J. Martinez-Beltran. 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 44:1556-1561.
4. Bukholm, G., T. Tannaes, A. B. Kjelsberg, and N. Smith-Erichsen. 2002. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect. Control Hosp. Epidemiol. 23:441-446.
5. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
6. Carmeli, Y., N. Troillet, A. Karchmer, and M. H. Samore. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132.
7. Chen, H. Y., M. Yuan, I. B. Ibrahim-Elmagboul, and D. M. Livermore. 1995. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeuginosa. J. Antimicrob. Chemother. 35:521-534.
8. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, P. L. Winokur, A. C. Gales, H. S. Sader, K. C. Kugler, and M. L. Beach. 1999. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:595-607.
9. Fagon, J. Y., J. Chastre, Y. Domart, J. L. Trouillet, and C. Gibert. 1996. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin. Infect. Dis. 23:538-542.
10. Fass, R. J., J. Barnishan, M. C. Solomon, and L. W. Ayers. 1996. In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob. Agents Chemother. 40:1412-1418.
11. Gales, A. C., R. N. Jones, K. R. Forward, J. Liñares, H. S. Sader, and J. Verhoef. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin. Infect. Dis. 32(Suppl. 2):S104-S113.
12. Gales, A. C., R. N. Jones, J. Turnidge, R. Rennie, and R. Ramphal. 2001. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S146-S155.
13. Harris, A., C. Torres-Viera, L. Venkataraman, P. DeGirolami, M. Samore, and Y. Carmeli. 1999. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis. 28:1128-1133.
14. Jones, R. N. 1999. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin. Infect. Dis. 29:495-502.
15. Jones, R. N., J. T. Kirby, M. L. Beach, D. J. Biedenbach, and M. J. Pfaller. 2002. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:239-243.
16. Jones, R. N., M. A. Pfaller, G. V. Doern, M. Erwin, R. Hollis, et al. 1998. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. 30:215-228.
17. Karlowsky, J. A., L. J. Kelly, C. Thornsberry, M. E. Jones, A. T. Evangelista, I. A. Critchley, D. F. Sahm, et al. 2002. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int. J. Antimicrob. Agents 19:21-31.
18. Kiska, D. L., and P. H. Gilligan. 1999. Pseudomonas, p. 517-525. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
19. Landman, D., J. M. Quale, D. Mayorga, A. Adediji, K. Vangala, J. Ravishankar, C. Flores, and S. Brooks. 2002. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162:1515-1520.
20. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.
21. Manikal, V. M., D. Landman, G. Saurina, E. Oydna, H. Lal, and J. M. Quale. 2000. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 31:101-106.
22. National Committee on Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. Vol. 22, no. 1. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. National Nosocomial Infections Surveillance (NNIS) System Report. 2000. Data summary from January 1992-April 2000, issued June 2000. Am. J. Infect. Control 28:429-448.
24. Pfaller, M. A., and R. N. Jones. 1997. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn. Microbiol. Infect. Dis. 28:157-163.
25. Pfaller, M. A., R. N. Jones, D. J. Biedenbach, and the MYSTIC Program Study Group (USA). 2001. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41:177-182.
26. Pfaller, M. A., R. N. Jones, G. V. Doern, and K. C. Kugler. 1998. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1762-1770.
27. Pollack, M. 2000. Pseudomonas aeruginosa, p. 2310-2335. In G. L. Mandell. J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.
28. Sahm, D. F., I. A. Critchley, L. J. Kelly, J. A. Karlowsky, D. C. Mayfield, C. Thornsberry, Y. R. Mauriz, and J. Kahn. 2001. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob. Agents Chemother. 45:267-274.
29. Sahm, D. F., M. K. Marsilio, and G. Piazza. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database - USA. Clin. Infect. Dis. 29:259-263.
30. Schreckenberger, P. C., and A. von Graevenitz. 1999. Acinetobacter, Achromobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative gram-negative rods, p. 539-560. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
31. Sofianou, D., A. Tsakris, K. Skoura, and J. Douboyas. 1997. Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. J. Antimicrob. Chemother. 40:740-742.
32. Tankovic, J., P. Legrand, G. De Gatines, V Chemineau, C. Brun-Buisson, and J. Duval. 1994. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J. Clin. Microbiol. 32:2677-2681.